AKBA - NASDAQ
Akebia Therapeutics, Inc.
$0.97
+3.6%Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotNo Dividend Yield Data
AKBA has not reported any dividend yield values in the available annual periods.
No Dividend Payout Ratio Data
AKBA has not reported any dividend payout ratio values in the available annual periods.
No Net Dividends Paid Data
AKBA has not reported any net dividends paid values in the available annual periods.
Akebia Therapeutics, Inc. Dividend History
AKBA Dividend Payment History
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Akebia Therapeutics, Inc. Payout Ratio Analysis
Dividend Sustainability Analysis
Payout Ratio
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF Payout Ratio
Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.
Sustainability
Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.
Related Guides
Continue your AKBA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.